Catalog No.
DHC13501
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Binetrakin, B-cell stimulatory factor 1, Pitrakinra, Lymphocyte stimulatory factor 1, IL-4, BSF-1, IL4, Interleukin-4
Concentration
2.15 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05112
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
SB-240683, CAS: 331243-22-2
Clone ID
Pascolizumab
[Current and future approaches for the treatment of inflammatory diseases of inferior respiratory tract], PMID: 16970111
A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma, PMID: 27637004
Modulating Interleukins and their Receptors Interactions with Small Chemicals Using In Silico Approach for Asthma, PMID: 30068279
Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma, PMID: 12296858
Targeting IL-4 for the Treatment of Atopic Dermatitis, PMID: 33062619
Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial., PMID:38527849
Mapping knowledge structure and research of the biologic treatment of asthma: A bibliometric study., PMID:36845128
Targeting IL-4 for the Treatment of Atopic Dermatitis., PMID:33062619
Modulating Interleukins and their Receptors Interactions with Small Chemicals Using In Silico Approach for Asthma., PMID:30068279
A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma., PMID:27637004
[Current and future approaches for the treatment of inflammatory diseases of inferior respiratory tract]., PMID:16970111
Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma., PMID:12296858
For research use only. Not for human or drug use.
